Xray Volume Imaging (Cone Beam CT) - Prostate Cancer

Phase 2

Completed

Brief Summary: Conformal dose escalated radiotherapy was adopted as the standard treatment technique at PMH for intermediate risk patients with localised disease in 1997. This technique provides a much smaller margin of error for treatment set-up and delivery than with conventional techniques. One way to ensure the accuracy of treatment delivery is to image the prostate position daily, prior to therapy, to allow for appropriate set-up corrections. To do so, imaging markers are implanted into the prostate under guided ultrasound (a standard procedure at PMH). However, there are disadvantages in using imaging markers which include added time to the treatment planning process, and an invasive procedure with a potential for discomfort, bleeding and infection. This study will investigate and compare X-ray volume imaging to the gold standard imaging markers.

Recruitment & Eligibility

Inclusion Criteria

Diagnosis of adenocarcinoma of the prostate
Patient undergoing escalated dose conformal external beam radiotherapy.
Patient has low or intermediate risk prognostic factors: all of PSA <21, Gleason score <8, clinical T category <T3, clinical N category 0 or X, M category 0 or X.
Informed consent

Exclusion Criteria

Primary Outcome Measures

Name	Time	Method
To evaluate he feasibility of daily X-ray volume imaging during conformal radiotherapy.

Secondary Outcome Measures

Name	Time	Method
To provide preliminary data concerning the relative utility of daily X-ray volume image matching compared to fiducial marker image matching.

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial